Monoclonal antibody disposition: A simplified PBPK model and its implications for the derivation and interpretation of classical compartment models

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 2, 2014, Pages 87-107

  Fronton, Ludivine ^a,b,c   Pilari, Sabine ^b,d   Huisinga, Wilhelm ^a  

^a UNIVERSITY OF POTSDAM   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ABBVIE INC   (United States)

Author keywords

Classical compartment model; Extravasation rate limited tissue model; mAb disposition; PBPK

Indexed keywords

ABCIXIMAB; ABCIXIMAB I 125; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGG1; MONOCLONAL ANTIBODY T84.66; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ENDOCYTOSIS; ENDOSOME; INTRACELLULAR SPACE; MOUSE; NONHUMAN; PARTITION COEFFICIENT; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMA VOLUME; PRIORITY JOURNAL; TISSUE DISTRIBUTION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; IMMUNOGLOBULIN G; MICE; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

EID: 84897578766     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9349-1     Document Type: Article

References (49)

1. Keizer R, Huitema A, Schellens J, Beijnen J (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493
2. Vugmeyster Y, Xu X, Theil F, Khawli L, Leach M (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 3(4):73
3. Jones H, Mayawala K, Poulin P (2013) Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J 15(2):377
4. Xiao J (2012) Pharmacokinetic models for FcRn-mediated IgG disposition. J Biomed Biotechnol 2012:282989
5. Baxter L, Zhu H, Mackensen D, Jain R (1994) Physiologically-based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissue and human tumor xenografts in nude mice. Cancer Res 54:1517
6. Ferl G, Wu M, Distefano AJ (2005) A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33(11):1640
7. Garg A, Balthasar J (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687
8. Davda J (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401
9. Urva S, Yang C, Balthasar J (2010) Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 99(3):1582
10. Shah D, Betts A (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67
11. Chen Y, Balthasar J (2012) Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J 14(4):850
12. Lu J, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of Bevacizumab in patients with solid tumors. Cancer Ther Pharmacol 62:779
13. Wiczling P, Rosenzweig M, Vaickus L, Jusko W (2010) Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, Otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 50:494
14. Dirks N, Nolting A, Kovar A, Meibohm B (2008) Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 48:267
15. Azzopardi N, Lecomte T, Ternant D, Piller F, Ohresser M, Watier H, Gamelin E, Paintaud G (2010) Population pharmacokinetics and exposition-PFS relationship of cetuximab in metastatic colorectal cancer. Population Approach Group Meeting
16. Lammertsvan Bueren J, Bleeker W, Bogh H, Houtkamp M, Schuurman J, van de Winkel J, Parren P (2006) Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66(15):7630
17. Mager D, Jusko W (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507
18. Mager D, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589
19. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573
20. Grimm H (2009) Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 36:407
21. Krippendorff B, Kuester K, Kloft C, Huisinga W (2009) Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn 36:239
22. Krippendorff B, Oyarzn DHW (2012) Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn 39(2):125
23. Shah D, Betts A (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs 5:2-297
24. Pilari S, Huisinga W (2010) Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 37:365405
25. Garg A (2007) Investigation of the role of FcRn in the absorption, distribution, and elimination of monoclonal antibodies. Ph.D. thesis, Faculty of the Graduate School of State University of New York at Buffalo
26. Hansen R, Balthasar J (2003) Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92(6):1206
27. El-Masri H, Portier C (1998) Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice. Drug Metab Dispos 26(6):585
28. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093
29. Kawai R, Lemaire M, Steimer J, Bruelisauer A, Niederberger W, Rowland M (1994) Physiologically based pharmacokinetic study on a cyclosporine derivative, SDZ IMM 125. J Pharmacokinet Pharmacodyn 22(5):327
30. Sarin H (2010) Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenesis Res 2:14
31. 2, and Fab' in mice. Cancer Res 46(8):3969
32. Brown R, Delp M, Lindstedt S, Rhomberg L, Beliles R (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407
33. Lagarias J, Reeds JA, Wright MH, Wright PE (1998) Convergence properties of the nelder-mead simplex method in low dimensions. J Optim Theory Appl 9(1):112
34. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu C, Ghetie VWES (1998) Functional expression of the MHC class i-related receptor, FcRn, in endothelial cells of mice. Int Immunol 10(9):12891298
35. Akilesh S, Christianson G, Roopenian D, Shaw A (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 179:4580
36. Montoyo H, Vaccaro C, Hafner M, Ober R, Mueller W, Ward E (2009) Conditional deletion of the MHC class i-related receptor FcRn reveals the sites of IgG homeostasis in mice. PNAS 106(8):27882793
37. Ghetie V, Hubbard J, Kim MF, Tsen J-K, Lee Y, Ward E (1996) Abnormally short serum half-lives of igg in 2-microglobulin-deficient mice. Eur J Immunol 26:690
38. Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259
39. Stoop J, Zegers BJM, Sander PC, Ballieux RE (1969) Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol 4:101
40. EMEA (2013) Summary of product characteristics of cetuximab
41. EMEA (2012) Summary of product characteristics of infliximab
42. EMEA (2013) Summary of product characteristics of rituximab
43. EMEA (2013) Summary of product characteristics of trastuzumab
44. EMEA (2013) Summary of product characteristics of golimumab
45. EMEA (2013) Summary of product characteristics of tocilizumab
46. Huisinga W, Solms A, Fronton L, Pilari S (2012) Modeling inter-individual variability in physiologically-based pharmacokinetics and its link to mechanistic covariate modeling. CPT 1:e4
47. Cao Y, Balthasar JP, Jusko WJ (2013) Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 40:597
48. Brambell F, Hemmings W, Morris I (1964) A theoretical model of gamma-globulin catabolism. Nat Biotechnol 203:1352
49. 2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93(11):5512